This is What Makes Axsome Therapeutics Inc. Stocks A Gamechanger?

Axsome Therapeutics Inc. [AXSM] stock prices are up down -2.48% to $52.22 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AXSM shares have lost -15.35% over the last week, with a monthly amount drifted -21.54%, and not seem to be holding up well over a long-time horizon.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


On 21, September 2022, Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference. In a post published today on Yahoo Finance, Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on Thursday, September 29, 2022 at 9:30 AM Eastern Time. The conference will be held at the Sofitel New York in New York City.

From an analyst’s perspective:

Previously, Morgan Stanley downgraded its rating to Equal-Weight on August 10, 2021, and dropped its price target to $34. On June 10, 2021, Berenberg initiated with a Buy rating and assigned a price target of $112 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $129 on January 08, 2021. Mizuho initiated its recommendation with a Buy and recommended $120 as its price target on December 16, 2020. BofA Securities started tracking with a Underperform rating for this stock on September 29, 2020, and assigned it a price target of $66. In a note dated September 10, 2020, Morgan Stanley initiated an Overweight rating and iterated a target price of $102 on this stock.

The stock price of Axsome Therapeutics Inc. [AXSM] has been fluctuating between $20.63 and $71.98 over the past year. Currently, Wall Street analysts expect the stock to reach $102.85 within the next 12 months. Axsome Therapeutics Inc. [NASDAQ: AXSM] shares were valued at $52.22 at the most recent close of the market. An investor can expect a potential return of 96.96% based on the average price forecast.

Analyzing the AXSM fundamentals

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 51.00 points at the first support level, and at 49.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 53.50, and for the 2nd resistance point, it is at 54.77.

Axsome Therapeutics Inc. [AXSM] reported earnings per share of -$1.03 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1/share, meaning a difference of $-0.03 and a surprise factor of -3.00%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were -$0.9 per share as compared to estimates of -$1.02 per share, a difference of $0.12 representing a surprise of 11.80%.

Ratios To Look Out For

It’s worth pointing out that Axsome Therapeutics Inc. [NASDAQ:AXSM]’s Current Ratio is 2.40. Also, the Quick Ratio is 3.75, while the Cash Ratio stands at 3.75.

Transactions by insiders

We now turn our attention to insider trading, which in the past 3 months has resulted in 0 insider buyings of 0 shares and 0 insider sellings of 0 shares. Recent insider trading involved JEFFS ROGER, Director, that happened on Nov 19 when 3950.0 shares were purchased. CHIEF FINANCIAL OFFICER, Pizzie Nick completed a deal on Nov 18 to buy 428.0 shares. Meanwhile, CHIEF FINANCIAL OFFICER Pizzie Nick bought 527.0 shares on Nov 18.